| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11260053 | MIRUM | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
May, 2031
(7 years from now) | |
| US11376251 | MIRUM | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
Oct, 2032
(8 years from now) | |
| US11229647 | MIRUM | Methods for treating cholestasis |
Feb, 2040
(15 years from now) | |
| US11497745 | MIRUM | Methods for treating cholestasis |
Feb, 2040
(15 years from now) | |
Livmarli is owned by Mirum.
Livmarli contains Maralixibat Chloride.
Livmarli has a total of 4 drug patents out of which 0 drug patents have expired.
Livmarli was authorised for market use on 29 September, 2021.
Livmarli is available in solution;oral dosage forms.
Livmarli can be used as treatment of cholestatic pruritus in patients with alagille syndrome (algs).
Drug patent challenges can be filed against Livmarli from 29 September, 2025.
The generics of Livmarli are possible to be released after 12 February, 2040.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 29, 2026 |
| Orphan Drug Exclusivity(ODE-429) | Mar 13, 2030 |
| New Indication(I-938) | Mar 13, 2027 |
| Orphan Drug Exclusivity(ODE-379) | Sep 29, 2028 |
| New Patient Population(NPP) | Mar 13, 2026 |
Drugs and Companies using MARALIXIBAT CHLORIDE ingredient
NCE-1 date: 29 September, 2025
Market Authorisation Date: 29 September, 2021
Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs)
Dosage: SOLUTION;ORAL
LIVMARLI family patents
